http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
급성 위식도정맥류 출혈에 내시경 N-butyl-2-cyanoacryl주입요법의 효과 TIPS의 치료 효과와의 비교 검토
노두영 ( No Du Yeong ),박선영 ( Park Seon Yeong ),주소영 ( Ju So Yeong ),박창환 ( Park Chang Hwan ),이완식 ( Lee Wan Sig ),주영은 ( Ju Yeong Eun ),김현수 ( Kim Hyeon Su ),최성규 ( Choe Seong Gyu ),유종선 ( Yu Jong Seon ),김세종 ( 대한소화기학회 2004 대한소화기학회지 Vol.43 No.3
Background/Aims: Though endoscopic therapies such as variceal ligation and sclerotherapy has been performed, bleeding from the large esophageal and gastric varices still poses significant risk of death. Decrease of portal pressure by TIPS (transjugular intrahepatic portosystemic shunt) or surgical shunt was indicated as cause of failure of endoscopic therapies. Treatment of N-butyl-2-cyanoacrylate has been especially effective for gastric variceal bleeding, but comparison with other treatments had not been reported yet. In this study, the effect of cyanoacrylate injection therapy was cross-examined with the result of TIPS in acute esophagogastric variceal bleedings. Methods: From April 1995 to June 2002, endoscopic cyanoacrylate injection therapy (43 cases) and TIPS (63 cases) were performed in our hospital. Each group was analysed regarding their clinical results including initial hemostasis rate, rebleeding rate, survival duration, mortality and morbidity. Results: Initial hemostasis rate was 95.3% in cyanoacrylate group and 92.1% in TIPS group. Cumulative probability of rebleeding was not different between two groups. Overall complication rates associated with the procedure were 50.8% in TIPS group and 9.3% in cyanoacrylate group. There was no significant difference between two groups in their survival rates. Conclusions: Cyanoacrylate injection therapy was relatively safe, and has comparable results with TIPS for uncontrollable and severe esophagogastric variceal bleedings. (Korean J Gastroenterol 2004;43:186-195)
경로통행시간추정을 위한 루프검지기의 최적 집계간격 결정
유소영(Yoo, So-Young),노정현(No, Jeong-Hyeon),박동주 대한교통학회 2003 대한교통학회 학술대회지 Vol.44 No.-
교통정보는 도로상에 구축된 첨단교통시스템을 통해 얻어지는 교통상황으로 운전자의 의사결정에 중요한 잣대가 된다. 특히, 통행시간정보는 운전자의 경로선정 및 교통체계 운영⋅관리측면에서 가장 영향력 있는 요소로 손꼽을 수 있다.
파장 분할 다중화 방식을 사용하는 광 전송망을 위한 분리 제어 신호 방식
노선식,김수현,소원호,김영천,No, Seon-Sik,Kim, Su-Hyeon,So, Won-Ho,Kim, Yeong-Cheon 대한전자공학회 2000 電子工學會論文誌-TC (Telecommunications) Vol.37 No.6
본 논문에서는 WDM 망에서 연결의 설정 및 해제를 효율적으로 제어하기 위한 분리 제어 신호방식 (Separated Control Signaling Protocol : SCSP)을 제안하였다. 제안된 분리 제어 신호 방식은 기존의 연결 제어 기능을 파장 및 각 노드 자원의 가용성을 점검하는 호 제어와 망 자원의 예약 및 할당을 위한 베어러 제어로 분리함으로써, 자원을 예약하기 전에 망 자원의 가용성을 점검하고 망 자원의 예약 시간을 줄일 수 있도록 하여 효율적으로 망 자원을 이용하며 또한 연결 설정 요청 수락률을 증가시킬 수 있다. 분리 신호 방식을 위한 노드 구조는 호 제어 기능을 수행하는 호 제어기와 베어러 제어 기능을 수행하는 베어러 제어기로 구성하였으며, 이에 대한 각 제어기의 기능과 제어기간의 정보 교환을 위한 제어 메시지 및 프리미티브를 정의하고 상태 천이도를 설계하였다. 이를 기반으로 분리 신호 방식에서의 연결 설정, 해제 및 실패에 대한 정보 흐름도를 작성하였다. 제안된 분리 제어 신호 방식의 성능 평가를 위해 다양한 시뮬레이션을 수행하였다. 성능 평가 결과 연결 요청 거절 확률과 자원의 이용률 측면에서 분리 제어 신호 방식이 기존의 통합 제어 신호 방식보다 우수한 성능을 보임을 확인할 수 있었다 In this paper, we propose a novel control signaling protocol that efficiently controls connection setup and increases the utilization of network resources. The proposed protocol, Separated Control Signaling Protocol(SCSP), separates bearer control from call control lot WDM optical networks. The main function of call control is to check the availability of network resources such as wavelengths and receivers at destination node. Bearer control is to reserve and assign wavelengths. The signaling architecture of this protocol consists of call controller and hearer controller The call controller handles call setup and release, activates the beater controller, and manages the status of call and bearer. The bearer controller reserves wavelengths, sets up bearer, tears down bearer. and notifies the status of beater to call controller. The state transition diagrams of each controller are designed. Using control messages and related primitives, the information flows for call setup and bearer setup, hearer teardown and call release, and reaction for setup failures are described to evaluate the performance. The simulation results show that the separated control signaling protocol is superior to conventional one in terms of call blocking probability and resource utilization.
Dieulafoy 양 병변에 의한 십이지장게실 출혈 1 예
김상현,김경환,이동현,송철수,정노원,박상제,김은규,하홍성,나일환,황윤이,성은영,최익수,신영기 대한소화기내시경학회 2001 Clinical Endoscopy Vol.23 No.1
Duodenal diverticula are first reported by Chomel in 1710. Duodenal diverticula are relatively common in adults with a prevalence of 23% in SRCP. The most duodenal diverticulum is asymptomatic. Complications such as obstruction, cholangitis, blliary stones, ulceration, perforation and hemorrhage can occur in approximately 10%. However, relatively few cases of bleeding from a duodenal diverticulum have been reported. The cause of bleeding from a duodenal diverticulum is uncertain and various suspected etiologies were suggested, such as ectopic gastric mucosa, stasis-induced ulceration, erosion into major vessels, aortoenteric fistuias, intradiverticujar polyp, aspirin-induced erosion. We report a case of a bleeding duodenal diverticulum by a Dieulafoy-like lesion and suggest this 1esion as one of posslble causes of blee4ng in duodenal diverticulum.
단순 복강경하 전자궁적출술 312예에 대한 임상적 분석
김유신 ( Kim Yu Sin ),이홍석 ( Lee Hong Seog ),권소영 ( Kwon So Yeong ),은미나 ( Eun Mi Na ),이경술 ( Lee Gyeong Sul ),박영세 ( Park Yeong Se ),정창조 ( Jeong Chang Jo ),김인현 ( Kim In Hyeon ),이정노 ( Lee Jeong No ) 대한산부인과학회 2004 Obstetrics & Gynecology Science Vol.47 No.1
목적 : 본원에서 시행한 단순 복강경하 전자궁적출술의 수술적응증, 수술시간, 수술 후 재원기간, 수술 전후 혈색소치의 변화, 합병증 등을 고찰하여 그 의학적 효용성을 분석하고자 한다. 연구 방법 : 2002년 1월부터 2003년 6월까지 포천중문의과대학 구미차병원 및 강남차병원에서 단순 복강경하 전자궁적출술을 시행한 312명의 환자를 대상으로 하였다. 결과 : 환자의 평균연령은 45.2세, 평균 출산력은 2.2회, 적출된 자궁의 평균무게는 272.3 g Objective : This study was conducted to evaluate the clinical efficacy of simple total laparoscopic hysterectomy in the aspect of operation indication, operation time, hospitalization day, blood loss, and postoperative complications. Methods : A retrospec
자궁샘근증의 한의학적 치료에 대한 국내 연구 동향 고찰
이성엽,이윤재,소민지,문혜연,김노현,서창용,도호정,송현섭,신재권,Lee, Sung-Yub,Lee, Yoon-Jae,So, Min-Ji,Moon, Hye-Yeon,Kim, No-Hyeon,Suh, Chang-Yong,Do, Ho-Jeong,Song, Hyun-Seop,Shin, Jae-Kwon 대한한방부인과학회 2017 大韓韓方婦人科學會誌 Vol.30 No.4
Objectives: The purpose of this study is to examines the domestic study trends on adenomyosis treated with Korean medicine. Methods: We investigated the studies on Korean medicine treatment for adenomyosis via searching 8 online databases. Results: As a result, 12 records (14 cases) were found to be analyzed according to their modes of diagnosis, symptoms, interventions, treatment period, follow up period and relevant outcomes. In diagnosis of adenomyosis, the most used method was ultrasonography. The most common complaint for patients with adenomyosis was dysmenorrhea. The most applied intervention for adenomyosis was herbal medication. Acupuncture was the second most used. Conclusions: Analyzing the domestic study trends would be helpful to establish a basic knowledge of the future study. It is anticipated that this review benefits the future in-depth study to confirm the efficacy of Korean medicine treatments for adenomyosis.
Ha Ra Gu,Su Cheol Park,Su Jin Choi,Jae Cheol Lee,You Cheoul Kim,Chul Ju Han,Ki Young Yang,김연주,Geum Youb Noh,So Hyeon No,Jae-Hoon Jeong 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)
( Ha Ra Gu ),( Su Cheol Park ),( Su Jin Choi ),( Jae Cheol Lee ),( You Cheoul Kim ),( Chul Ju Han ),( Jin Kim ),( Ki Young Yang ),( Yeon Joo Kim ),( Geum Youb Noh ),( So Hyeon No ),( Jae Hoon Jeong ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)